A Phase 1B/2 Study of OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors and Activating Mutations in the RAS Pathway (Phase 1B) and in Patients with Advanced NRAS-Mutated Melanoma

The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have with Advanced NRAS-Mutated Melanoma. The purpose of this part of the study is to find out how OKI-179 will absorb in the human body when taken with binimetinib, what side effects happen, and whether the drugs have an effect on the cancer.OKI-179 and binimetinib are both drugs that act against a specific enzyme in the body involved in helping cancer cells live and grow. Because the study drugs are not approved medications for your cancer, OKI-179 and binimetinib are considered investigational, which means that they are not approved by the FDA.

The length of time you spend in the study depends on the status of your disease and how your body responds to the study drug (up to about 2 years).

Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT05340621

uvacancertrials@hscmail.mcc.virginia.edu